Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- OPC-34712's Promise as New Antipsychotic Confirmed in PII: Otsuka
June 13, 2011
- Yakult: Pharmaceutical Sales Up 10.8% Driven by Elplat
June 13, 2011
- Mirabegron Recommended for Approval for Treatment of OAB
June 13, 2011
- DSP, Kyorin Announce Results of Domestic PII Trial of Ranirestat
June 13, 2011
- Ajinomoto: Pharma Operating Profits Down 32% due to Higher R&D Costs
June 13, 2011
- Korosho to Conduct Survey on Economic Conditions in Healthcare
June 13, 2011
- KW-6002 Found Effective for PD in Domestic PIII Study: Kyowa Kirin
June 13, 2011
- Asahi Kasei Pharma: Sales Up 3.4% Driven by 3.5-Fold Increase in Sales of Recomodulin
June 13, 2011
- Council to Discuss Revision of Copayments for OTC-like Drugs
June 13, 2011
- JAK Inhibitor Tofacitinib Reduces Symptoms of RA: Pfizer Inc.
June 13, 2011
- ASKA: First Net Loss since Merger due to Earthquake
June 13, 2011
- Industry FTC Revises GL on Business Entertainment Practices
June 13, 2011
- Taiyo to Announce New Business Strategy around October
June 13, 2011
- Nippon Shinyaku: Sales Up 0.9% to ¥63.5 Bil. Driven by Cialis, Lunabell
June 6, 2011
- Some GE Houses to Delay Listing Actos Generics for 1 Year
June 6, 2011
- Sales Up 33.1% Driven by CMO Business: CMIC
June 6, 2011
- Sawai to Launch Actos Generics with Full Indications in June
June 6, 2011
- Cervarix Ranked No. 1 in GP Market in March: RepTrack Survey
June 6, 2011
- Towa Ready to Launch Generic Actos with Full Indications
June 6, 2011
- Daiichi Sankyo, AZ to Copromote Denosumab in Japan
June 6, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…